Antiviral therapy in chronic hepatitis E: a systematic review
Direct costs of first-generation protease inhibitors for the treatment of genotype 1 chronic hepatitis C viral infection
Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels
Memory re-differentiation and reduced lymphocyte activation in chronic HCV-infected patients receiving direct-acting antivirals
Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure
The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients
A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1–4 hepatitis C virus
Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort
Chronic hepatitis C virus infection is associated with increased risk of preterm birth: a meta-analysis of observational studies
Disease burden of chronic hepatitis C among immigrants in Canada
Association of IFNL3 and IFNL4 polymorphisms with liver-related mortality in a multiracial cohort of HIV/HCV-coinfected women
Changing 14-year trends in the epidemiology of hepatitis B virus infection in rural and urban Central–Eastern European areas
T- and B-cell responses and previous exposure to hepatitis B virus in ‘anti-HBc alone’ patients
Serum HBsAg kinetics and usefulness of interferon-inducible protein 10 serum in HBeAg-negative chronic hepatitis B patients treated with tenofovir disoproxil fumarate